In short, today's compound testing news was very good. Positive results with multiple compounds - didn't see 15 coming ! - and work continuing.
What wasn't referred to today was the target endpoints previously mentioned in the last shareholder letter, other than the basic positive response against viral replication, and even this was nothing but a headline. I was expecting much more detail about the results, but rather, we received the methodology process. This is very interesting and a strong positive in my opinion. They are keeping the science to themselves, and in hindsight, this is understandable and normal.
For those who have been reading over recent months any of the numerous research papers on C-19 research, you'll recall that they are divided into distinct sections: An overall outline including a hypothesis, introduction and further elaboration on their hypothesis, methodology, and conclusion. Even though today's results were not a research paper, I was expecting further science behind it. Rather, we had a description of standard lab testing. But with this, we musn't overlook what we were told. Results are positive and continuing.
But for me, what wasn't said is more important.
Naturally, the market was a little uncertain when it had such great expectations, but still held up very well, which demonstrates the underlying strength in the stock. I expect this to continue as smart investors become informed of the potential. This is apart from any other progress in Biotron's other developments that can come anytime. As noted, the further testing will be much quicker. I expect the remainder of 2020 to be significantly more productive from an investors perspective.
Expand
